Acorda Therapeutics (DB:CDG) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CDG Overzicht aandelen

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Meer informatie

CDG fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 10.3% per jaar gegroeid

Risicoanalyse

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €15M )

Aandeelhouders zijn het afgelopen jaar verwaterd

Acorda Therapeutics, Inc. Concurrenten

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

Paion

XTRA:PA8

€2.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Acorda Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$8.42
52 Week Hoogtepunt	US$21.80
52 Week Laag	US$5.64
Bèta	1.43
11 maand verandering	0%
3 maanden verandering	-6.83%
1 Jaar Verandering	10.25%
33 jaar verandering	-83.90%
5 jaar verandering	-99.70%
Verandering sinds IPO	-98.76%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CDG	DE Biotechs	DE Markt
7D	0%	-0.7%	-0.02%
1Y	10.2%	-17.2%	8.2%

Rendement versus industrie: CDG overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -17.2 % opleverde.

Rendement versus markt: CDG overtrof de German markt, die het afgelopen jaar een rendement opleverde van 8.2 %.

Prijsvolatiliteit

Is CDG's price volatile compared to industry and market?
CDG volatility
CDG Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van CDG is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van CDG in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	111	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Acorda Therapeutics zich tot de beurswaarde?
CDG fundamentele statistieken
Marktkapitalisatie	€14.12m
Inkomsten(TTM)	-€19.42m
Inkomsten(TTM)	€108.53m

0.1x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is CDG overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CDG resultatenrekening (TTM)
Inkomsten	US$116.91m
Kosten van inkomsten	US$27.38m
Brutowinst	US$89.53m
Overige uitgaven	US$110.45m
Inkomsten	-US$20.92m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-16.84
Brutomarge	76.58%
Nettowinstmarge	-17.89%
Schuld/Eigen Vermogen Verhouding	259.6%

Hoe presteerde CDG op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

CDG Overzicht aandelen

Beloningen

Risicoanalyse

Acorda Therapeutics, Inc. Concurrenten

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:PA8

€2.6m

XTRA:HPHA

€103.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40